俄亥俄州 的 多发性骨髓瘤 临床试验
俄亥俄州 有 46 项针对 多发性骨髓瘤 的研究正在招募参与者。
俄亥俄州 的城市
官方研究文本（英文）
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Cincinnati
- Research Site, Cleveland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT04973605A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University Hospitals Cleveland Medical Center, Cleveland
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06500884A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Ohio State University, Columbus
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07393282Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus
招募中2 期
60 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06052826A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
- 以及另外 4 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05552222A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Cleveland Clinic, Cleveland
招募中2 期
18 至 80 岁 · 所有性别 · 更新于 2026年9月25日 · NCT07149857A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Gabrail Cancer Center, Canton
- The Christ Hospital, Cincinnati
- Dayton Physicians Network Urology, Dayton
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07518186Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06465316TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Cincinnati Medical Center, Cincinnati
- Kettering Health, Kettering
- West Chester Hospital, West Chester
招募中2 期
12 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月21日 · NCT07648264Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
招募中观察性研究
2 Months · 所有性别 · 更新于 2026年9月16日 · NCT00900198A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Cleveland Clinic, Cleveland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Oncology Hematology Care, Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06297226Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- TriHealth Cancer and Blood Institute, Cincinnati
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT07555938A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Cleveland
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月27日 · NCT07681596Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
- Gabrail Cancer & Research Center, Canton
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月24日 · NCT06087653MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- 以及另外 5 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月24日 · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Canton
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月19日 · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OhioHealth O'Bleness Hospital, Athens
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- 以及另外 15 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月19日 · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Ohio State University, Columbus
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月18日 · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月18日 · NCT05651932Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Cincinnati
- Research Site, Cleveland
- Research Site, Columbus
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月14日 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Ohio State University Comprehensive Cancer Center, Columbus
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月12日 · NCT07280013A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
- The Ohio State University /ID# 271336, Columbus
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年7月21日 · NCT06892522A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年7月13日 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- The Ohio State University James Cancer Hospital, Columbus
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年7月8日 · NCT05137054Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年7月8日 · NCT07657312Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
招募中观察性研究欢迎健康志愿者
19 至 110 岁 · 所有性别 · 更新于 2026年6月29日 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Indu and Raj Soin Medical Center, Beavercreek
- Saint Elizabeth Boardman Hospital, Boardman
- Dayton Physicians LLC-Miami Valley South, Centerville
- 以及另外 17 项
招募中3 期
所有年龄段 · 所有性别 · 更新于 2026年6月10日 · NCT05561387Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus
招募中2 期
19 岁及以上 · 所有性别 · 更新于 2026年6月4日 · NCT06974786Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Cincinnati, Cincinnati
- Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
- Ohio State Medical Center, James Cancer Center, Columbus
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年6月4日 · NCT05243797Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- The Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年6月2日 · NCT05145400A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
招募中
18 岁及以上 · 所有性别 · 更新于 2026年5月27日 · NCT07609030A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 104, Columbus
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年5月12日 · NCT07582432Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
招募中1 期
13 岁及以上 · 所有性别 · 更新于 2026年5月5日 · NCT04771572A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Columbus
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年4月22日 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Oncology Hematology Care, Cincinnati
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年4月22日 · NCT05972135Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Ohio State University James Cancer Hospital, Columbus
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年4月20日 · NCT03761108A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
招募中1/2 期
12 岁及以上 · 所有性别 · 更新于 2026年3月24日 · NCT04988555数据来自 ClinicalTrials.gov，检索日期：2026年9月30日。每项研究自行设定入选标准，由研究团队决定谁能参与。